Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients WithEGFR-Mutated Advanced Non–Small Cell Lung Cancer

JAMA Oncology ◽

10.1001/jamaoncol.2018.1395 ◽

2018 ◽

Vol 4 (8) ◽

pp. 1080 ◽

Author(s):

Pedro N. Aguiar ◽

Benjamin Haaland ◽

Wungki Park ◽

Pui San Tan ◽

Auro del Giglio ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Small Cell Lung ◽

First Line Treatment

Download Full-text

PCN116 COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) PLUS PLATINUM-PEMETREXED FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN FRANCE

Value in Health ◽

10.1016/j.jval.2019.09.313 ◽

2019 ◽

Vol 22 ◽

pp. S458

Author(s):

C. Chouaid ◽

L. Bensimon ◽

A. Millier ◽

E. Clay ◽

R. Insinga ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Small Cell Lung ◽

First Line Treatment

Download Full-text

PCN100 COST-EFFECTIVENESS OF GEFITINIB VERSUS DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN

Value in Health ◽

10.1016/s1098-3015(11)71995-7 ◽

2010 ◽

Vol 13 (7) ◽

pp. A270 ◽

Author(s):

J Jacob ◽

M Henriksson ◽

D Brattström

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Small Cell Lung ◽

Doublet Chemotherapy ◽

First Line Treatment

Download Full-text

PCN152 - COST EFFECTIVENESS OF ALECTINIB IN THE FIRST LINE TREATMENT OF ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN TURKEY

Value in Health ◽

10.1016/j.jval.2018.09.235 ◽

2018 ◽

Vol 21 ◽

pp. S40

Author(s):

E. Öksüz ◽

S. Malhan ◽

L. Yanik ◽

E. Koc ◽

E. Erdogan-Ciftci ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Small Cell Lung ◽

Alk Positive ◽

First Line Treatment

Download Full-text

PCN36 Cost-Effectiveness Analysis of Pembrolizumab Versus Nivolumab As the First-LINE Treatment for Advanced and Metastatic NON-SMALL CELL LUNG Cancer in Germany

Value in Health Regional Issues ◽

10.1016/j.vhri.2020.07.086 ◽

2020 ◽

Vol 22 ◽

pp. S11

Author(s):

J. Verma ◽

D. Verma ◽

A. Maria

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Small Cell Lung ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

Cancer Management and Research ◽

10.2147/cmar.s293983 ◽

2021 ◽

Vol Volume 13 ◽

pp. 4263-4270

Author(s):

Longfeng Zhang ◽

Na Li ◽

Maobai Liu ◽

Bin Zheng ◽

Zhijuan Wu ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Small Cell Lung ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

CN5 - COST-EFFECTIVENESS OF PEMBROLIZUMAB VERSUS STANDARD-OF-CARE CHEMOTHERAPIES FOR FIRST-LINE TREATMENT OF PD-L1 POSITIVE (≥50%) METASTATIC NON-SMALL CELL LUNG CANCER IN FRANCE

Value in Health ◽

10.1016/j.jval.2018.09.022 ◽

2018 ◽

Vol 21 ◽

pp. S4

Author(s):

C. Chouaid ◽

L. Bensimon ◽

E. Clay ◽

A. Millier ◽

L. Lévy-Bachelot ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Standard Of Care ◽

Line Treatment ◽

Small Cell Lung ◽

First Line Treatment

Download Full-text

PCN37 Cost-Effectiveness Analysis of Pembrolizumab Versus Nivolumab As the First-LINE Treatment for Advanced and Metastatic NON-SMALL CELL LUNG Cancer in France

Value in Health Regional Issues ◽

10.1016/j.vhri.2020.07.087 ◽

2020 ◽

Vol 22 ◽

pp. S11

Author(s):

J. Verma ◽

D. Verma ◽

A. Maria

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Small Cell Lung ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

PCN97 Cost-Effectiveness of Atezolizumab Monotherapy Versus Pembrolizumab Monotherapy for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer

Value in Health ◽

10.1016/j.jval.2021.04.189 ◽

2021 ◽

Vol 24 ◽

pp. S37

Author(s):

C.W. Lin ◽

K. Rosettie ◽

S.P. Bilir ◽

H. Celik ◽

S. Abogunrin ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Small Cell Lung ◽

First Line Treatment

Download Full-text

Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer

Advances in Therapy ◽

10.1007/s12325-021-01788-6 ◽

2021 ◽

Author(s):

Ye Peng ◽

Xiaohui Zeng ◽

Liubao Peng ◽

Qiao Liu ◽

Lidan Yi ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Small Cell Lung ◽

First Line Treatment

Download Full-text

Atezolizumab compared to chemotherapy for first-line treatment in non-small cell lung cancer with high PD-L1 expression: a cost-effectiveness analysis from US and Chinese perspectives

Annals of Translational Medicine ◽

10.21037/atm-21-4294 ◽

2021 ◽

Vol 0 (0) ◽

pp. 0-0

Author(s):

Shuqiao Cheng ◽

Rui Pei ◽

Jianhuang Li ◽

Bin Li ◽

Lanhua Tang ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Small Cell Lung ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text